Oncternal Therapeutics Inc (ONCT) Stock Price, Quote, News and Overview
NASDAQ:ONCT - Nasdaq - US68236P2065 - Common Stock - Currency: USD
ONCT Quote, Performance and Key Statistics
Oncternal Therapeutics Inc
NASDAQ:ONCT (12/2/2024, 8:00:01 PM)
After market: 0.61 +0.08 (+15.84%)0.5266
-0.17 (-24.11%)
The current stock price of ONCT is 0.5266 USD. In the past month the price decreased by -64.89%. In the past year, price decreased by -93.89%.
ONCT Latest News, Press Releases and Analysis
Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
SAN DIEGO, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced updated data from its Phase 1/2...
Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives
SAN DIEGO, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT) (the “Company”) today announced its decision to discontinue its...
ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024
ONCT stock results show that Oncternal Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Oncternal Therapeutics (NASDAQ:ONCT) just reported results for the second quart...
ONCT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.94 | 338.64B | ||
| AMGN | AMGEN INC | 15.36 | 163.65B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 955.17 | 125.45B | ||
| GILD | GILEAD SCIENCES INC | 22.53 | 124.38B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.45 | 77.46B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.87B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 35.53B | ||
| BNTX | BIONTECH SE-ADR | N/A | 29.42B | ||
| ONC | BEIGENE LTD-ADR | N/A | 24.41B | ||
| NTRA | NATERA INC | N/A | 23.35B | ||
| BIIB | BIOGEN INC | 8.94 | 21.28B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.71 | 15.97B |
Related stock screener links
About ONCT
Company Profile
Oncternal Therapeutics, Inc. engages in the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. The company is headquartered in San Diego, California and currently employs 27 full-time employees. The company went IPO on 2004-02-03. The firm is focused on the development of oncology therapies for the treatment of patients with cancers that have critical unmet medical needs. The Company’s product candidates include ONCT-534, ONCT-808, Zilovertamab, and ONCT-216. ONCT-534 is a dual-action androgen receptor inhibitor (DAARI), for the treatment of advanced castration-resistant prostate cancer (CRPC) and other androgen receptor (AR) driven diseases. ONCT-808 is an autologous chimeric antigen receptor (CAR-T) therapy that targets ROR1 for the treatment of hematologic malignancies and solid tumors. Zilovertamab is an investigational, humanized, monoclonal antibody designed to inhibit the function of Receptor tyrosine kinase-like Orphan Receptor 1 (ROR1). Zilovertamab has been evaluated in an investigator-initiated Phase 1b study of zilovertamab in combination with docetaxel in patients with mCRPC.
Company Info
Oncternal Therapeutics Inc
12230 El Camino Real, Suite 230
San Diego CALIFORNIA 92130 US
CEO: James B. Breitmeyer
Employees: 27
Company Website: https://www.oncternal.com/
Investor Relations: https://investor.oncternal.com/
Phone: 18584341113
ONCT FAQ
What is the stock price of ONCT?
The current stock price of ONCT is 0.5266 USD.
What is the symbol for Oncternal Therapeutics Inc stock?
The exchange symbol of Oncternal Therapeutics Inc is ONCT and it is listed on the Nasdaq exchange.
On which exchange is ONCT stock listed?
ONCT stock is listed on the Nasdaq exchange.
Is ONCT a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ONCT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ONCT.
Does ONCT stock pay dividends?
ONCT does not pay a dividend.
What is the Price/Earnings (PE) ratio of ONCT?
ONCT does not have a PE ratio as the earnings reported over the last twelve months were negative (-11.69).
ONCT Technical Analysis
ONCT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ONCT. The financial health of ONCT is average, but there are quite some concerns on its profitability.
ONCT Financial Highlights
Over the last trailing twelve months ONCT reported a non-GAAP Earnings per Share(EPS) of -11.69. The EPS decreased by 18.82% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -221.62% | ||
| ROE | -377.95% | ||
| Debt/Equity | 0 |
ONCT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 43% to ONCT. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 10.27% and a revenue growth 161.75% for ONCT